Importer of Controlled Substances; Notice of Application, 67758-67759 [E7-23188]
Download as PDF
<![CDATA[
67758
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–614]
In the Matter of: Certain Wireless
Communication Chips and Chipsets,
and Products Containing Same,
Including Wireless Handsets and
Network Interface Cards; Notice of
Commission Determination Not To
Review an Initial Determination
Granting Respondent’s Motion To
Terminate the Investigation Due to a
Pending Arbitration
U.S. International Trade
Commission.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review the presiding administrative law
judge’s (‘‘ALJ’’) initial determination
(‘‘ID’’) (Order No. 5) granting
respondent’s motion to terminate the
investigation due to a pending
arbitration.
FOR FURTHER INFORMATION CONTACT:
Clint Gerdine, Esq., Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
708–2310. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on September 21, 2007, based on a
complaint filed by Nokia Inc. of Irving,
Texas and Nokia Corporation of Espoo,
Finland (collectively ‘‘Nokia’’). 72 FR
54069. The complaint, as supplemented,
alleges violations of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, in the importation into the
United States, the sale for importation,
and the sale within the United States
after importation of certain wireless
communication chips and chipsets, and
products containing same, including
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
wireless handsets and network interface
cards, by reason of infringement of
certain claims of U.S. Patent Nos.
7,236,761; 6,714,091; 6,292,474;
5,896,562; and 5,752,172. The
complaint further alleges the existence
of a domestic industry. The
Commission’s notice of investigation
named QUALCOMM, Inc.
(‘‘Qualcomm’’) of San Diego, California
as the respondent.
On October 18, 2007, the ALJ issued
an ID (Order No. 5) granting
respondent’s motion to terminate the
investigation due to a pending
arbitration. On October 25, 2007, Nokia
filed a petition for review of the ALJ’s
ID. On November 1, 2007, Qualcomm
and the Commission investigative
attorney filed briefs in opposition to
Nokia’s petition for review. The
Commission has determined not to
review the subject ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in
sections 210.21(a)(2) and 210.42(h) of
the Commission’s Rules of Practice and
Procedure, 19 CFR 210.21(a)(2),
210.42(h).
By order of the Commission.
Issued: November 21, 2007.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–23220 Filed 11–29–07; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on May 8,
2007, American Custom Chemicals
Corporation, 6650 Lusk Boulevard,
Suite B102, San Diego, California 92121,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Sufentanil (9740), a basic class of
controlled substance listed in schedule
II.
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
The company plans to import the
listed controlled substance for research
purposes only.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than December 31,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–43746), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 20, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–23187 Filed 11–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
E:\FR\FM\30NON1.SGM
30NON1
Federal Register / Vol. 72, No. 230 / Friday, November 30, 2007 / Notices
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on August
16, 2007, Clinical Supplies
Management, Inc., 4733 Amber Valley
Parkway, Fargo, North Dakota 58104,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
classes of controlled substances listed in
schedule I and II:
Drug
Schedule
rwilkins on PROD1PC63 with NOTICES
Tetrahydrocannabinols (7370) .....
Sufentanil (9740) ..........................
I
II
The company plans to import the
listed controlled substances for clinical
trials, research, analytical purposes, and
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA 22152; and must
be filed no later than December 31,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
VerDate Aug<31>2005
16:27 Nov 29, 2007
Jkt 214001
Dated: November 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–23188 Filed 11–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a registration under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with Title 21
Code of Federal Regulations (CFR),
1301.34(a), this is notice that on October
12, 2007, Lipomed Inc., One Broadway,
Cambridge, Massachusetts 02142, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
I:
Drug
Schedule
Methcathinone (1237) ..................
N-ethylamphetamine (1475) .........
Gamma
Hydroxybutyric
Acid
(2010).
2,5-Dimethoxy-4-[n]propylthiophenethylamine
(7348).
I
I
I
I
The company plans to import the
listed controlled substances for clinical
trials, research, analytical purposes, and
distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537, or any being sent via express
mail should be sent to Drug
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
67759
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 8701 Morrissette
Drive, Springfield, VA. 22152; and must
be filed no later than December 31,
2007.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: November 20, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–23184 Filed 11–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 1, 2007,
Norac Inc., 405 S. Motor Avenue, P.O.
Box 577, Azusa, California 91702–3232,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Tetrahydrocannabinols
(7370), a basic class of controlled
substance listed in schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for formulation into the pharmaceutical
controlled substance Marinol.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537, or any being
sent via express mail should be sent to
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 72, Number 230 (Friday, November 30, 2007)]
[Notices]
[Pages 67758-67759]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-23188]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
registration under 21 U.S.C. 952(a)(2) authorizing the importation of
[[Page 67759]]
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with Title 21 Code of Federal Regulations
(CFR), 1301.34(a), this is notice that on August 16, 2007, Clinical
Supplies Management, Inc., 4733 Amber Valley Parkway, Fargo, North
Dakota 58104, made application to the Drug Enforcement Administration
(DEA) to be registered as an importer of the basic classes of
controlled substances listed in schedule I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Sufentanil (9740).......................... II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
clinical trials, research, analytical purposes, and distribution to its
customers.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537, or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 8701 Morrissette Drive,
Springfield, VA 22152; and must be filed no later than December 31,
2007.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e) and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, (40 FR 43745-46), all
applicants for registration to import a basic class of any controlled
substances in schedule I or II are and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
Dated: November 19, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-23188 Filed 11-29-07; 8:45 am]
BILLING CODE 4410-09-P
